Antibiotic Resistance Market Synopsis

Antibiotic Resistance Market Size Was Valued at USD 10.16 Billion in 2023, and is Projected to Reach USD 30.9 Billion by 2032, Growing at a CAGR of 13.19% From 2024-2032.

The antibiotic resistance market can be described as the industry that encompasses all the products and services targeted at addressing antibiotic resistance, a major worldwide health concern that occurs when microorganisms develop mechanisms that make drugs used to control them ineffective. This market encompasses diagnostic and therapeutic measures and other interventions aimed at controlling the emergence and spread of resistant pathogens that are necessary to guarantee efficient treatment of bacterial infections. Since antibiotic resistance remains a critical issue negatively impacting public health systems globally, the market has the essential function of contributing to the building of breakthrough methods for redeeming lost effectiveness in current antibiotics and identifying new ones.

• The market is currently expanding significantly, mainly due to the rising trend in the number of antibiotic-resistant infections, which is a problem both for clinicians and key decision-makers globally. WHO estimates that antibiotic resistance is responsible for half a million deaths each year and could cause two million deaths in the near future if efforts towards its fight are not put into practice. The teams are pressured by chronic diseases together with the percentage of geriatric population that has exponentially increased, which increases the need for antibiotics thus worsening the problem. State and health care organizations are strengthening scientific and experimental work, which is focused on solving this urgent problem, so global progress is observed in the development of diagnostic methods, new therapeutic therapies, and effective antibiotic usage systems.
• In besides the increasing signalled threats associated with public health, the antibiotic resistance market has been experiencing increasing regulatory sensitivity as well. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for example are shouldering a new tighter policy on approval and utilization of antibiotics encouraging the synthesis of new antimicrobial agents but reducing on the existing ones. This environment promotes innovation, as firms in the pharmaceutical industry are forced to seek out new chemical entities and multiple drug regimens. Moreover, there is an increase in the number of public private partnerships to enhance cooperation of all stakeholders to speed up the discovery of corresponding treatments and preventive measures.

Antibiotic Resistance Market Trend Analysis

Rise of Novel Antibiotic Approaches

• Another factor tending towards the shift of considerable sized funding to the segment of the antibiotic resistance market is the emerging interest in the innovative antibiotics and other treatment. Current approaches to the derivation of traditional antibiotics heavily flawed with many drawbacks such as long drug approval procedures, high trial failure rates. Therefore, there is huge focus on identifying new approaches that can help in preventing resistant bacteria, including bacteriophage therapy, antimicrobial peptides and CRISPR technologies. All these inventive techniques do not only offer potential remedial measures against exploits resistant attacks but also suggested more fruitful paths of development, thus contributing a sustainable approach to consumption of antibiotics.
• The government driven rates such as the antibiotic stewardship programs are driving this aspect since health care facilities value the need to use the antibiotics wisely in order to retain their function. These epidemiology programs emphasize in the enhancement of managing the infections, discouraging the prescription of medicines that are not necessary and encouraging the use of other forms of treatment where necessary. By avoiding the unnecessary prescription of antibiotics, that to the wrong patients and for the wrong disease, the healthcare providers are addressing not only the current problems of antibiotic resistance but also culture creativity in finding ways of solving this problem that threatens the whole globe.

Expansion of Diagnostic Solutions

• Antibiotic resistance itself is a huge market that is expected to grow fast, especially in diagnostics domain. The ability to detect resistant strains of bacteria quickly and with high certainty is important to guide the manner in which patients are treated with antibiotics and to prevent their overuse. Point of care testing and the tailored molecular diagnostic tools in infections are likely to provide better solutions for this disease by shortening turnaround times. Thus, as awareness of the role of diagnostics as a key growth driver rises, so should investments in this segment offer major opportunities to innovators in diagnostics.

Antibiotic Resistance Market Segment Analysis:

Antibiotic Resistance Market Segmented on the basis of drug, pathogen and disease.

By Type, Beta-lactams segment is expected to dominate the market during the forecast period

• The Beta-lactams segment is expected to have the highest market share of the antibiotic resistance market within the forecast period the use of this segment is extensive and its use effective in combating many bacterial infections. This category of antibiotics is widely renown and comprises of penicillin, cephalosporin, and carbapenem. They remain useful due to further study devoted to the eradication of resistance factors as well as new formulations that improve the effectiveness of these drugs. These factors put them as the preferred choice among healthcare providers trying to find new treatment options for difficult to treat infections and should favour prospects in the segment. Also, with increased prevalence of the combination therapies such as the Beta-lactams and other agents to fight resistance elevates their role in stewardship.

By Pathogen, Gram-negative bacteria segment expected to held the largest share

• The Currently, antibiotic resistance market is segmented on the basis of bacteria and, based on analysis, gram-negative bacteria segment possesses higher market share than gram positive bacteria due to complications related with these pathogens in healthcare sector. She continued that the groups of bacteria that are particularly problematic due to their intrinsic and intermittent resistance and for the fact that they can easily exchange genetic material include Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. This is an inconvenience when seeking a cure because Gram-negative infections tend to be more dangerous than their Gram-positive counterparts. Hospitals the world over are constantly facing increased instances of multidrug resistant GN infections and therefore, there is a great need to develop better diagnostics and therapeutic agents that will address these bacteria. Therefore, the authorization of new antibiotics and other treatment options relevant to Gram-negative bacteria will probably generate considerable growth within this area of the market.

Antibiotic Resistance Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• In 2023, North America became the largest market in antibiotic resistance market taking nearly 45% share in the world market. The leadership can be explained by the availability of health care, high R & D investment and effective policies focused on the fight against antibiotic resistance in the region. The existence of key participants of the pharmaceutical industry and centres for research in America contributes to creating an environment that encourages development of programs and new forms of therapy in North America.

Active Key Players in the Antibiotic Resistance Market

• Astellas Pharma (Japan)
• AstraZeneca (UK)
• Biomerieux (France)
• Cubist Pharmaceuticals (USA)
• Eli Lilly and Company (USA)
• GlaxoSmithKline (UK)
• ImmunoPrecise Antibodies (Canada)
• Johnson & Johnson (USA)
• Merck & Co. (USA)
• Novartis (Switzerland)
• Paratek Pharmaceuticals (USA)
• Pfizer (USA)
• Roche (Switzerland)
• Sanofi (France)
• Tetraphase Pharmaceuticals (USA), Other key Players.

Key Industry Developments in the Antibiotic Resistance Market:

• In May 2023, For patients in China, Paratek Pharmaceuticals, Inc. and Zai Lab (Shanghai) Co., Ltd. collaborated to develop and market omadacycline, a novel treatment based on tetracycline chemistry.
• In May 2023, In order to commercialize and license anti-infective medications, such as BAXDELA, KIMYRSA, ORBACTIV, and VABOMERE, in Canada, Melinta Therapeutics, LLC and Xediton Pharmaceuticals Inc. engaged into a private agreement.
• In November 2023, In the United States, Melinta Therapeutics LLC and Venatorx Pharmaceuticals, Inc. established a license agreement for a strategic alliance. The goal of this partnership is to commercialize cefepime-taniborbactam, a combination antibiotic intended to treat adult hospital-acquired bacterial pneumonia and complex UTIs.

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Antibiotic Resistance Market by Drug-class
 4.1 Antibiotic Resistance Market Snapshot and Growth Engine
 4.2 Antibiotic Resistance Market Overview
 4.3 Beta-lactams
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Beta-lactams: Geographic Segmentation Analysis
 4.4 macrolides
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 macrolides: Geographic Segmentation Analysis
 4.5 tetracyclines
  4.5.1 Introduction and Market Overview
  4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.5.3 Key Market Trends, Growth Factors and Opportunities
  4.5.4 tetracyclines: Geographic Segmentation Analysis
 4.6 fluoroquinolones
  4.6.1 Introduction and Market Overview
  4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.6.3 Key Market Trends, Growth Factors and Opportunities
  4.6.4 fluoroquinolones: Geographic Segmentation Analysis

Chapter 5: Antibiotic Resistance Market by Pathogen
 5.1 Antibiotic Resistance Market Snapshot and Growth Engine
 5.2 Antibiotic Resistance Market Overview
 5.3 Gram-negative bacteria
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Gram-negative bacteria: Geographic Segmentation Analysis
 5.4 Gram-positive bacteria
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Gram-positive bacteria: Geographic Segmentation Analysis

Chapter 6: Antibiotic Resistance Market by Disease
 6.1 Antibiotic Resistance Market Snapshot and Growth Engine
 6.2 Antibiotic Resistance Market Overview
 6.3 Respiratory infections
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Respiratory infections: Geographic Segmentation Analysis
 6.4 Urinary tract infections
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Urinary tract infections: Geographic Segmentation Analysis
 6.5 Bloodstream infections
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Bloodstream infections: Geographic Segmentation Analysis
 6.6 & Others
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 & Others: Geographic Segmentation Analysis

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Benchmarking
  7.1.2 Antibiotic Resistance Market Share by Manufacturer (2023)
  7.1.3 Industry BCG Matrix
  7.1.4 Heat Map Analysis
  7.1.5 Mergers and Acquisitions
  
 7.2 ASTELLAS PHARMA (JAPAN)
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Role of the Company in the Market
  7.2.5 Sustainability and Social Responsibility
  7.2.6 Operating Business Segments
  7.2.7 Product Portfolio
  7.2.8 Business Performance
  7.2.9 Key Strategic Moves and Recent Developments
  7.2.10 SWOT Analysis
 7.3 ASTRAZENECA (UK)
 7.4 BIOMERIEUX (FRANCE)
 7.5 CUBIST PHARMACEUTICALS (USA)
 7.6 ELI LILLY AND COMPANY (USA)
 7.7 GLAXOSMITHKLINE (UK)
 7.8 IMMUNOPRECISE ANTIBODIES (CANADA)
 7.9 JOHNSON & JOHNSON (USA)
 7.10 MERCK & CO (USA)
 7.11 NOVARTIS (SWITZERLAND)
 7.12 PARATEK PHARMACEUTICALS (USA)
 7.13 PFIZER (USA)
 7.14 ROCHE (SWITZERLAND)
 7.15 SANOFI (FRANCE)
 7.16 TETRAPHASE PHARMACEUTICALS (USA)
 7.17 OTHER KEY PLAYERS

Chapter 8: Global Antibiotic Resistance Market By Region
 8.1 Overview
 8.2. North America Antibiotic Resistance Market
  8.2.1 Key Market Trends, Growth Factors and Opportunities
  8.2.2 Top Key Companies
  8.2.3 Historic and Forecasted Market Size by Segments
  8.2.4 Historic and Forecasted Market Size By Drug-class
  8.2.4.1 Beta-lactams
  8.2.4.2 macrolides
  8.2.4.3 tetracyclines
  8.2.4.4 fluoroquinolones
  8.2.5 Historic and Forecasted Market Size By Pathogen
  8.2.5.1 Gram-negative bacteria
  8.2.5.2 Gram-positive bacteria
  8.2.6 Historic and Forecasted Market Size By Disease
  8.2.6.1 Respiratory infections
  8.2.6.2 Urinary tract infections
  8.2.6.3 Bloodstream infections
  8.2.6.4 & Others
  8.2.7 Historic and Forecast Market Size by Country
  8.2.7.1 US
  8.2.7.2 Canada
  8.2.7.3 Mexico
 8.3. Eastern Europe Antibiotic Resistance Market
  8.3.1 Key Market Trends, Growth Factors and Opportunities
  8.3.2 Top Key Companies
  8.3.3 Historic and Forecasted Market Size by Segments
  8.3.4 Historic and Forecasted Market Size By Drug-class
  8.3.4.1 Beta-lactams
  8.3.4.2 macrolides
  8.3.4.3 tetracyclines
  8.3.4.4 fluoroquinolones
  8.3.5 Historic and Forecasted Market Size By Pathogen
  8.3.5.1 Gram-negative bacteria
  8.3.5.2 Gram-positive bacteria
  8.3.6 Historic and Forecasted Market Size By Disease
  8.3.6.1 Respiratory infections
  8.3.6.2 Urinary tract infections
  8.3.6.3 Bloodstream infections
  8.3.6.4 & Others
  8.3.7 Historic and Forecast Market Size by Country
  8.3.7.1 Bulgaria
  8.3.7.2 The Czech Republic
  8.3.7.3 Hungary
  8.3.7.4 Poland
  8.3.7.5 Romania
  8.3.7.6 Rest of Eastern Europe
 8.4. Western Europe Antibiotic Resistance Market
  8.4.1 Key Market Trends, Growth Factors and Opportunities
  8.4.2 Top Key Companies
  8.4.3 Historic and Forecasted Market Size by Segments
  8.4.4 Historic and Forecasted Market Size By Drug-class
  8.4.4.1 Beta-lactams
  8.4.4.2 macrolides
  8.4.4.3 tetracyclines
  8.4.4.4 fluoroquinolones
  8.4.5 Historic and Forecasted Market Size By Pathogen
  8.4.5.1 Gram-negative bacteria
  8.4.5.2 Gram-positive bacteria
  8.4.6 Historic and Forecasted Market Size By Disease
  8.4.6.1 Respiratory infections
  8.4.6.2 Urinary tract infections
  8.4.6.3 Bloodstream infections
  8.4.6.4 & Others
  8.4.7 Historic and Forecast Market Size by Country
  8.4.7.1 Germany
  8.4.7.2 UK
  8.4.7.3 France
  8.4.7.4 Netherlands
  8.4.7.5 Italy
  8.4.7.6 Russia
  8.4.7.7 Spain
  8.4.7.8 Rest of Western Europe
 8.5. Asia Pacific Antibiotic Resistance Market
  8.5.1 Key Market Trends, Growth Factors and Opportunities
  8.5.2 Top Key Companies
  8.5.3 Historic and Forecasted Market Size by Segments
  8.5.4 Historic and Forecasted Market Size By Drug-class
  8.5.4.1 Beta-lactams
  8.5.4.2 macrolides
  8.5.4.3 tetracyclines
  8.5.4.4 fluoroquinolones
  8.5.5 Historic and Forecasted Market Size By Pathogen
  8.5.5.1 Gram-negative bacteria
  8.5.5.2 Gram-positive bacteria
  8.5.6 Historic and Forecasted Market Size By Disease
  8.5.6.1 Respiratory infections
  8.5.6.2 Urinary tract infections
  8.5.6.3 Bloodstream infections
  8.5.6.4 & Others
  8.5.7 Historic and Forecast Market Size by Country
  8.5.7.1 China
  8.5.7.2 India
  8.5.7.3 Japan
  8.5.7.4 South Korea
  8.5.7.5 Malaysia
  8.5.7.6 Thailand
  8.5.7.7 Vietnam
  8.5.7.8 The Philippines
  8.5.7.9 Australia
  8.5.7.10 New Zealand
  8.5.7.11 Rest of APAC
 8.6. Middle East & Africa Antibiotic Resistance Market
  8.6.1 Key Market Trends, Growth Factors and Opportunities
  8.6.2 Top Key Companies
  8.6.3 Historic and Forecasted Market Size by Segments
  8.6.4 Historic and Forecasted Market Size By Drug-class
  8.6.4.1 Beta-lactams
  8.6.4.2 macrolides
  8.6.4.3 tetracyclines
  8.6.4.4 fluoroquinolones
  8.6.5 Historic and Forecasted Market Size By Pathogen
  8.6.5.1 Gram-negative bacteria
  8.6.5.2 Gram-positive bacteria
  8.6.6 Historic and Forecasted Market Size By Disease
  8.6.6.1 Respiratory infections
  8.6.6.2 Urinary tract infections
  8.6.6.3 Bloodstream infections
  8.6.6.4 & Others
  8.6.7 Historic and Forecast Market Size by Country
  8.6.7.1 Turkey
  8.6.7.2 Bahrain
  8.6.7.3 Kuwait
  8.6.7.4 Saudi Arabia
  8.6.7.5 Qatar
  8.6.7.6 UAE
  8.6.7.7 Israel
  8.6.7.8 South Africa
 8.7. South America Antibiotic Resistance Market
  8.7.1 Key Market Trends, Growth Factors and Opportunities
  8.7.2 Top Key Companies
  8.7.3 Historic and Forecasted Market Size by Segments
  8.7.4 Historic and Forecasted Market Size By Drug-class
  8.7.4.1 Beta-lactams
  8.7.4.2 macrolides
  8.7.4.3 tetracyclines
  8.7.4.4 fluoroquinolones
  8.7.5 Historic and Forecasted Market Size By Pathogen
  8.7.5.1 Gram-negative bacteria
  8.7.5.2 Gram-positive bacteria
  8.7.6 Historic and Forecasted Market Size By Disease
  8.7.6.1 Respiratory infections
  8.7.6.2 Urinary tract infections
  8.7.6.3 Bloodstream infections
  8.7.6.4 & Others
  8.7.7 Historic and Forecast Market Size by Country
  8.7.7.1 Brazil
  8.7.7.2 Argentina
  8.7.7.3 Rest of SA

Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies
Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research